{
    "clinical_study": {
        "@rank": "124506", 
        "arm_group": [
            {
                "arm_group_label": "SB3", 
                "arm_group_type": "Experimental", 
                "description": "SB3, single dose of 6 mg/kg via intravenous infusion (study drug)"
            }, 
            {
                "arm_group_label": "EU sourced Herceptin\u00ae", 
                "arm_group_type": "Active Comparator", 
                "description": "EU sourced Herceptin\u00ae, single dose of 6 mg/kg via intravenous infusion (reference drug)"
            }, 
            {
                "arm_group_label": "US sourced Herceptin\u00ae", 
                "arm_group_type": "Active Comparator", 
                "description": "US sourced Herceptin\u00ae, single dose of 6 mg/kg via intravenous infusion (reference drug)"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to compare the pharmacokinetics, safety, tolerability and\n      immunogenicity of SB3 and Herceptin\u00ae (EU sourced Herceptin\u00ae and US sourced Herceptin\u00ae) in\n      healthy male subjects."
        }, 
        "brief_title": "Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of SB3 in Healthy Male Subjects", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male subjects\n\n          -  Have a body weight between 60.0 and 94.9 kg and a body mass index between 18.0 and\n             29.9 kg/m\u00b2, inclusive.\n\n        Exclusion Criteria:\n\n          -  history of and/or current clinically significant gastrointestinal, renal, hepatic,\n             cardiovascular, haematological (including pancytopenia, aplastic anaemia or blood\n             dyscrasia), pulmonary, neurologic, metabolic (including known diabetes mellitus),\n             psychiatric or significant allergic disease excluding mild asymptomatic allergies.\n\n          -  history of and/or current cardiac disease\n\n          -  previously received any monoclonal antibody or fusion protein.\n\n          -  history of cancer including lymphoma, leukaemia and skin cancer.\n\n          -  Have received live vaccine(s) within 30 days prior to Screening or who will require a\n             vaccine(s) between Screening and the End of Study visit.\n\n          -  intake medication with a half-life > 24 h within 1 month or 10 half-lives of the\n             medication prior to the administration of investigational product."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "109", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 27, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02075073", 
            "org_study_id": "SB3-G11-NHV", 
            "secondary_id": "2013-004112-21"
        }, 
        "intervention": [
            {
                "arm_group_label": "SB3", 
                "intervention_name": "SB3", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "EU sourced Herceptin\u00ae", 
                "intervention_name": "EU sourced Herceptin\u00ae", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "US sourced Herceptin\u00ae", 
                "intervention_name": "US sourced Herceptin\u00ae", 
                "intervention_type": "Biological"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Trastuzumab"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Pharmacokinetics", 
        "lastchanged_date": "May 19, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Berlin", 
                    "country": "Germany"
                }, 
                "name": "Samsung Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Randomised, Double-blind, Three-arm, Parallel Group, Single-dose Study to Compare the Pharmacokinetics, Safety, Tolerability, and Immunogenicity of Three Formulations of Trastuzumab (SB3, EU Sourced Herceptin\u00ae and US Sourced Herceptin\u00ae) in Healthy Male Subjects", 
        "overall_official": {
            "affiliation": "Samsung Bioepis Co., Ltd.", 
            "last_name": "Saumsung Bioepis", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Germany: Paul-Ehrlich-Institut", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Area under the concentration-time curve from time zero to infinity (AUCinf)", 
                "safety_issue": "No", 
                "time_frame": "57 days"
            }, 
            {
                "measure": "Maximum serum concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "57 days"
            }, 
            {
                "measure": "Area under the concentration-time curve from time zero to the last quantifiable concentration (AUClast)", 
                "safety_issue": "No", 
                "time_frame": "57 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02075073"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Time to Cmax (Tmax)", 
            "safety_issue": "No", 
            "time_frame": "57 days"
        }, 
        "source": "Samsung Bioepis Co., Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Samsung Bioepis Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}